{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T22:18:56Z","timestamp":1782598736280,"version":"3.54.5"},"reference-count":48,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.3892\/or.2015.4294","type":"journal-article","created":{"date-parts":[[2015,9,18]],"date-time":"2015-09-18T11:12:22Z","timestamp":1442574742000},"page":"3120-3130","source":"Crossref","is-referenced-by-count":19,"title":["Autocrine interferon-\u03b3 may affect malignant behavior and sensitivity to tamoxifen of MCF-7 via estrogen receptor \u03b2 subtype"],"prefix":"10.3892","volume":"34","author":[{"given":"XIU LONG","family":"NIU","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YUE","family":"WANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZHI","family":"YAO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HONGJIE","family":"DUAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZHIJUN","family":"LI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WENXING","family":"LIU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HONGJIAN","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WEI MIN","family":"DENG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2015,9,18]]},"reference":[{"key":"key20180107212632_b1-or-34-06-3120","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"key20180107212632_b2-or-34-06-3120","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/jnci\/djn330","article-title":"Increasing breast cancer incidence in China: The numbers add up","volume":"100","author":"Ziegler","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"key20180107212632_b3-or-34-06-3120","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.steroids.2012.11.001","article-title":"Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis","volume":"78","author":"Yue","year":"2013","journal-title":"Steroids"},{"key":"key20180107212632_b4-or-34-06-3120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0014-5793(96)00782-X","article-title":"ER beta: Identification and characterization of a novel human estrogen receptor","volume":"392","author":"Mosselman","year":"1996","journal-title":"FEBS Lett"},{"key":"key20180107212632_b5-or-34-06-3120","first-page":"370","article-title":"Oestrogen receptors in breast cancer: Basic mechanisms and clinical implications","volume":"7","author":"Williams","year":"2013","journal-title":"E Cancer Med Sci"},{"key":"key20180107212632_b6-or-34-06-3120","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/path.1436","article-title":"Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model","volume":"201","author":"Skliris","year":"2003","journal-title":"J Pathol"},{"key":"key20180107212632_b7-or-34-06-3120","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.7314\/APJCP.2013.14.10.6081","article-title":"Prognostic significance of interactions between ER alpha and ER beta and lymph node status in breast cancer cases","volume":"14","author":"Han","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"key20180107212632_b8-or-34-06-3120","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.critrevonc.2004.02.001","article-title":"Estrogens and their receptors in breast cancer progression: A dual role in cancer proliferation and invasion","volume":"51","author":"Platet","year":"2004","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20180107212632_b9-or-34-06-3120","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1038\/sj.onc.1203828","article-title":"Estrogen receptor beta acts as a dominant regulator of estrogen signaling","volume":"19","author":"Pettersson","year":"2000","journal-title":"Oncogene"},{"key":"key20180107212632_b10-or-34-06-3120","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1152\/physrev.2001.81.4.1535","article-title":"Mechanisms of estrogen action","volume":"81","author":"Nilsson","year":"2001","journal-title":"Physiol Rev"},{"key":"key20180107212632_b11-or-34-06-3120","first-page":"2434","article-title":"Estrogen receptor beta protein in human breast cancer: Correlation with clinical tumor parameters","volume":"63","author":"Fuqua","year":"2003","journal-title":"Cancer Res"},{"key":"key20180107212632_b12-or-34-06-3120","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/sj.bjc.6602183","article-title":"Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers","volume":"91","author":"O'Neill","year":"2004","journal-title":"Br J Cancer"},{"key":"key20180107212632_b13-or-34-06-3120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/B978-0-12-416673-8.00004-6","article-title":"Modulation of estrogen receptor alpha activity and expression during breast cancer progression","volume":"93","author":"Kerdivel","year":"2013","journal-title":"Vitam Horm"},{"key":"key20180107212632_b14-or-34-06-3120","first-page":"6784","article-title":"Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10","volume":"63","author":"Stassi","year":"2003","journal-title":"Cancer Res"},{"key":"key20180107212632_b15-or-34-06-3120","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","article-title":"Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer","volume":"29","author":"Mahmoud","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180107212632_b16-or-34-06-3120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF02967457","article-title":"Interleukin-4 and breast cancer","volume":"7","author":"Nagai","year":"2000","journal-title":"Breast Cancer"},{"key":"key20180107212632_b17-or-34-06-3120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1479-5876-9-35","article-title":"Tumor escape and progression of HER-2\/neu negative breast cancer under immune pressure","volume":"9","author":"Kmieciak","year":"2011","journal-title":"J Transl Med"},{"key":"key20180107212632_b18-or-34-06-3120","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ajpath.2011.10.040","article-title":"Modulation of IFN-\u03b3 receptor 1 expression by AP-2\u03b1 influences IFN-\u03b3 sensitivity of cancer cells","volume":"180","author":"Chen","year":"2012","journal-title":"Am J Pathol"},{"key":"key20180107212632_b19-or-34-06-3120","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/1471-2407-7-158","article-title":"Influence of IFN-gamma and its receptors in human breast cancer","volume":"7","author":"Garc\u00eda-Tu\u00f1\u00f3n","year":"2007","journal-title":"BMC Cancer"},{"key":"key20180107212632_b20-or-34-06-3120","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2249.1994.tb06029.x","article-title":"Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells","volume":"95","author":"Obiri","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"key20180107212632_b21-or-34-06-3120","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1172\/JCI116205","article-title":"Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4","volume":"91","author":"Obiri","year":"1993","journal-title":"J Clin Invest"},{"key":"key20180107212632_b22-or-34-06-3120","first-page":"465","article-title":"Immunostaining of interleukin-4 receptor on human renal cell carcinoma","volume":"12","author":"Varricchio","year":"1993","journal-title":"Lymphokine Cytokine Res"},{"key":"key20180107212632_b23-or-34-06-3120","first-page":"275","article-title":"Inhibition of colon and breast carcinoma cell growth by interleukin-4","volume":"52","author":"Toi","year":"1992","journal-title":"Cancer Res"},{"key":"key20180107212632_b24-or-34-06-3120","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/sj.cdd.4402305","article-title":"Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4","volume":"15","author":"Todaro","year":"2008","journal-title":"Cell Death Differ"},{"key":"key20180107212632_b25-or-34-06-3120","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/sj.bjc.6602416","article-title":"Interleukin-4 enhances proliferation of human pancreatic cancer cells: Evidence for autocrine and paracrine actions","volume":"92","author":"Prokopchuk","year":"2005","journal-title":"Br J Cancer"},{"key":"key20180107212632_b26-or-34-06-3120","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.4049\/jimmunol.172.9.5467","article-title":"IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins","volume":"172","author":"Conticello","year":"2004","journal-title":"J Immunol"},{"key":"key20180107212632_b27-or-34-06-3120","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1158\/0008-5472.CAN-05-2514","article-title":"Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells","volume":"66","author":"Todaro","year":"2006","journal-title":"Cancer Res"},{"key":"key20180107212632_b28-or-34-06-3120","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0960-0760(98)00031-4","article-title":"Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells","volume":"65","author":"Turgeon","year":"1998","journal-title":"J Steroid Biochem Mol Biol"},{"key":"key20180107212632_b29-or-34-06-3120","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10549-013-2549-3","article-title":"Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers","volume":"139","author":"Hong","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"key20180107212632_b30-or-34-06-3120","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/1541-7786.MCR-08-0093","article-title":"Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer","volume":"6","author":"Li","year":"2008","journal-title":"Mol Cancer Res"},{"key":"key20180107212632_b31-or-34-06-3120","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1073\/pnas.1323719111","article-title":"Differential expression of estrogen receptor \u03b1, \u03b21, and \u03b22 in lobular and ductal breast cancer","volume":"111","author":"Huang","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107212632_b32-or-34-06-3120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-0031-1299592","article-title":"The role of estrogen receptor-\u03b2 in breast cancer","volume":"30","author":"Murphy","year":"2012","journal-title":"Semin Reprod Med"},{"key":"key20180107212632_b33-or-34-06-3120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jsbmb.2003.07.003","article-title":"Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells","volume":"87","author":"Tonetti","year":"2003","journal-title":"J Steroid Biochem Mol Biol"},{"key":"key20180107212632_b34-or-34-06-3120","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1038\/sj.onc.1207765","article-title":"ERbeta exerts multiple stimulative effects on human breast carcinoma cells","volume":"23","author":"Hou","year":"2004","journal-title":"Oncogene"},{"key":"key20180107212632_b35-or-34-06-3120","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.steroids.2008.04.006","article-title":"ERbeta in breast cancer -onlooker, passive player, or active protector?","volume":"73","author":"Fox","year":"2008","journal-title":"Steroids"},{"key":"key20180107212632_b36-or-34-06-3120","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/sj.bjc.6603295","article-title":"Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours","volume":"95","author":"Skliris","year":"2006","journal-title":"Br J Cancer"},{"key":"key20180107212632_b37-or-34-06-3120","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/me.2004-0381","article-title":"Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells","volume":"19","author":"Monroe","year":"2005","journal-title":"Mol Endocrinol"},{"key":"key20180107212632_b38-or-34-06-3120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10549-006-9229-5","article-title":"Assessment of multiple different estrogen receptor-beta antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions","volume":"100","author":"Weitsman","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"key20180107212632_b39-or-34-06-3120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1530\/ERC-13-0444","article-title":"Support of a bi-faceted role of estrogen receptor \u03b2 (ER\u03b2) in ER\u03b1-positive breast cancer cells","volume":"21","author":"Jonsson","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"key20180107212632_b40-or-34-06-3120","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1186\/bcr1648","article-title":"Oestrogen receptor negative breast cancers exhibit high cytokine content","volume":"9","author":"Chavey","year":"2007","journal-title":"Breast Cancer Res"},{"key":"key20180107212632_b41-or-34-06-3120","first-page":"223","article-title":"Th1\/Th2 balance: The hypothesis, its limitations, and implications for health and disease","volume":"8","author":"Kidd","year":"2003","journal-title":"Altern Med Rev"},{"key":"key20180107212632_b42-or-34-06-3120","doi-asserted-by":"crossref","first-page":"11207","DOI":"10.1158\/0008-5472.CAN-06-0017","article-title":"Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts","volume":"66","author":"Hartman","year":"2006","journal-title":"Cancer Res"},{"key":"key20180107212632_b43-or-34-06-3120","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1210\/er.2004-0015","article-title":"Aromatase inhibitors in the treatment of breast cancer","volume":"26","author":"Brueggemeier","year":"2005","journal-title":"Endocr Rev"},{"key":"key20180107212632_b44-or-34-06-3120","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1200\/JCO.2005.01.172","article-title":"Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase","volume":"23","author":"Gutierrez","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180107212632_b45-or-34-06-3120","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.2174\/138161212800626139","article-title":"Estrogen receptor beta in cancer: An attractive target for therapy","volume":"18","author":"Gallo","year":"2012","journal-title":"Curr Pharm Des"},{"key":"key20180107212632_b46-or-34-06-3120","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1200\/JCO.2007.14.2968","article-title":"Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy","volume":"26","author":"Honma","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180107212632_b47-or-34-06-3120","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.canlet.2013.05.031","article-title":"Reversal of ER-\u03b2 silencing by chromatin modifying agents overrides acquired tamoxifen resistance","volume":"337","author":"Pitta","year":"2013","journal-title":"Cancer Lett"},{"key":"key20180107212632_b48-or-34-06-3120","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1038\/onc.2012.335","article-title":"Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer","volume":"32","author":"Razandi","year":"2013","journal-title":"Oncogene"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2015.4294\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T21:26:44Z","timestamp":1515360404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2015.4294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,18]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,9,18]]},"published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.3892\/or.2015.4294"],"URL":"https:\/\/doi.org\/10.3892\/or.2015.4294","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,18]]}}}